ST萬林(603117.SH):控股股東將變更為蘇瑞投資
格隆匯3月28日丨ST萬林(603117.SH)公佈,2023年3月25日,公司接到公司控股股東共青城鉑瑞的通知,共青城鉑瑞與蘇瑞投資於2023年3月25日簽署了《股份轉讓協議》,共青城鉑瑞擬向蘇瑞投資協議轉讓其持有的公司無限售流通股74,628,057股,佔公司總股本的11.79%。
本次權益變動導致公司控股股東由共青城鉑瑞變更為蘇瑞投資,實際控制人不發生變更,仍為樊繼波先生。
蘇瑞投資受讓共青城鉑瑞持有的上市公司股份系同一實際控制人樊繼波先生控制的不同主體之間的轉讓,為樊繼波先生控制的企業的股權內部調整。蘇瑞投資承諾本次協議收購的資金來源均為合法的自有資金或銀行貸款。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.